Metronidazole Vaginal Gel, 1.3 %
Brand Names: Metronidazole Vaginal Gel, 1.3 % Generic
Methodology & AI Transparency ⓘ
Metronidazole Vaginal Gel, 1.3 % Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Metronidazole vaginal gel is indicated for the treatment of bacterial vaginosis in females 12 years of age and older.
- 2 Real-world patient consensus: Tracked across 17 patient dosage logs with a 89% satisfaction benchmark (RxCUI 1608253).
- 3 Typical cash cost range: Dispensing cost comparison spans $15.95 mail/discount cash up to $39.08 uninsured retail (federal NADAC $0.1839).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Metronidazole Vaginal Gel, 1.3 % include nausea (9.6%), headache (11.8%), diarrhea (10.5%).
Ask our AI Specialists anything about Metronidazole Vaginal Gel, 1.3 %
Metronidazole Vaginal Gel, 1.3 % Mechanism, CYP450 Pathways & DailyMed Monograph
Metronidazole vaginal gel is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. Metronidazole vaginal gel is a nitroimidazole antimicrobial indicated for the treatment of bacterial vaginosis in females 12 years of age and older. ( 1 )
12.1 Mechanism of Action Metronidazole is an antimicrobial drug . As an active nitroimidazole antimicrobial moiety (Encube Ethicals, Inc.), Metronidazole Vaginal Gel, 1.3 % modulates physiological signaling proportional to 65 mg/5g Gel exposure and hepatorenal clearance (SPL 2025-09-15).
Clinical clearance of Metronidazole Vaginal Gel, 1.3 % (Nitroimidazole Antimicrobial) relies on local esterase/enzymatic cleavage of metronidazole vaginal gel, 1.3 % with minimal hepatic cytochrome burden with a Localized tissue retention for Metronidazole Vaginal Gel, 1.3 % with minimal systemic plasma half-life half-life; patients absorbing at < 5% transdermal or mucosal systemic uptake from Metronidazole Vaginal Gel, 1.3 % bioavailability typically observe target onset around initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (metronidazole vaginal gel, 1.3 %).
FDA clinical labeling for Metronidazole Vaginal Gel, 1.3 % restricts administration in 4 contraindications; history of hypersensitivity to metronidazole, parabens, other ingredients of the formulation, or other nitroimidazole derivatives (4.1); concomitant use of disulfiram or within 2 weeks of disulfiram ( 4.2 , 7.1 ) across 65 mg/5g Gel, 5 g, 65 mg, 1.3%, with self-reported patient tracking dominated by headache (11.8% of reports), diarrhea (10.5% of reports), nausea (9.6% of reports).
Concurrent Metronidazole Vaginal Gel, 1.3 % exposure alters anticoagulant pharmacodynamics, requiring closer hemorrhagic surveillance.
Assess baseline hepatic panels and interacting prescriptions when starting Metronidazole Vaginal Gel, 1.3 % (nitroimidazole antimicrobial).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS
- History of hypersensitivity to metronidazole, parabens, other ingredients of the formulation, or other nitroimidazole derivatives (4.1)
- Concomitant use of disulfiram or within 2 weeks of disulfiram ( 4.2 , 7.1 )
Logged Side-Effect Incidence (17 Reports)
Metronidazole Vaginal Gel, 1.3 % Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Metronidazole Vaginal Gel, 1.3 %)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effectiveness of postoperative oral administration of cephalexin and: What a 210-Participant Study Found Post-operative administration of cephalexin and metronidazole for 48-h post-cesarean delivery among obese women, in addition to the standard pre-operative prophylaxis, reduced the overall rate of surgical site infection and... Antimicrobial resistance and infection control • 2022-12-05 • Phase III Randomized Trial | N = 210 | 88/100 | PMID 36471429 ↗ |
| Can This Approach Help? Inside the Latest Research on A phase III, multicenter, gold-standard blind, randomized clinical trial to In Chinese adult participants with cIAI, C/T plus metronidazole was noninferior to meropenem, with comparable safety. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35987467 ↗ |
| Can This Approach Help? Inside the Latest Research on Metronidazole gel (0.75%) in Japanese patients with rosacea: A randomized, Of these, treatment-related, treatment-emergent side effects occurred in 9.2% and 6.2% in the metronidazole and the vehicle group, respectively, but there were no new safety concerns. The Journal of dermatology • 2022-03-15 • Phase III Randomized Trial | N = 65 | 88/100 | PMID 34854112 ↗ |
Metronidazole Vaginal Gel, 1.3 % Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1839/unit (~$5.52/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $39.08 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $15.95 / mo | View logs ↓ |
Metronidazole Vaginal Gel, 1.3 % Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Metronidazole Vaginal Gel, 1.3 % RxNorm Concept ID | 1608253 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1839 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $39.08 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $15.95 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Metronidazole Vaginal Gel, 1.3 % Patient Community, Cohort Filters & Dosage Logs
Deterministic Metronidazole Vaginal Gel, 1.3 % reference combining NIH RxNorm (1608253), Medicaid NADAC ($0.1839/unit), and anonymous cohort outcomes (89% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Metronidazole Vaginal Gel, 1.3 % community threads and patient logs by age, biological sex, dosage, and treatment duration.